Evidence map›Paper›PMID 37359115›Full record

ArticleJGH open : an open access journal of gastroenterology and hepatology2023

The prevalence and treatment outcomes of

Pakkapon Rattanachaisit, Chuti Burana, Aunchalee Jaroenlapnopparat, Sirikorn Vongseenin, Supakarn Chaithongrat, Rungsun Rerknimitr, Duangporn Werawatganon

Open access · goldAbstract read
In one paragraph

Article in JGH open : an open access journal of gastroenterology and hepatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. RefractoryJGH open : an open access journal of gastroenterology and hepatology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Pakkapon RattanachaisitDepartment of Physiology, Faculty of Medicine Chulalongkorn University and Center of Excellence in Alternative and Complementary Medicine for Gastrointestinal and Liver Diseases Bangkok Thailand.
Chuti BuranaDepartment of Physiology, Faculty of Medicine Chulalongkorn University and Center of Excellence in Alternative and Complementary Medicine for Gastrointestinal and Liver Diseases Bangkok Thailand.
Aunchalee JaroenlapnopparatDepartment of Medicine, Faculty of Medicine Chulalongkorn University Bangkok Thailand.
Sirikorn VongseeninDepartment of Medicine, Faculty of Medicine Chulalongkorn University Bangkok Thailand.
Supakarn ChaithongratDepartment of Medicine, Faculty of Medicine Chulalongkorn University Bangkok Thailand.
Rungsun RerknimitrDepartment of Medicine, Faculty of Medicine Chulalongkorn University Bangkok Thailand.
Duangporn WerawatganonDepartment of Physiology, Faculty of Medicine Chulalongkorn University and Center of Excellence in Alternative and Complementary Medicine for Gastrointestinal and Liver Diseases Bangkok Thailand.ORCID https://orcid.org/0000-0001-8847-9690
Chulalongkorn University · TH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Aim: Methods: We retrospectively reviewed the results of the urea breath test (UBT) performed at the King Chulalongkorn Memorial Hospital between 2018 and 2021. The prevalence of HP infection was evaluated in dyspeptic patients undergoing UBT screening. In patients with known HP infection, the treatment regimen and the success rate in each patient were recorded. Results: One-thousand nine-hundred and two patients were included in this study. The prevalence of HP infection in dyspeptic patients was 20.77% (UBT was positive in 65 out of 313 patients). Of the 1589 patients who received the first treatment regimen, 1352 (85.08%) had a negative UBT result. Patients who failed in each treatment regimen were treated with subsequent regimens. The overall success rates for the second, third, and fourth regimens were 69.87% (109 of 156 patients), 53.85% (14 of 26 patients), and 50% (3 of 6 patients), respectively. Univariate logistic regression analysis found that using lansoprazole was associated with failure of treatment with OR = 2.11 (95% CI: 1.14-3.92, Conclusion: Current primary HP treatment regimens have an eradication rate of >80%. Even though the previous regimens failed, without available antibiotic sensitivity results, the subsequent regimens were successful by at least 50%. In cases of multiple-treatment failure and where antibiotic sensitivity tests were unavailable, continuing to change regimens could provide satisfactory results.

Indexed as

eradication rateH. pyloritreatment regimenurea breath test

Identifiers

PMID37359115
PMCPMC10290267
OpenAlexW4378473382

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.